PD-1 Resistant Head and Neck Cancer (HNC) Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com

PD-1 Resistant Head and Neck Cancer (HNC) Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com




PD-1 Resistant Head and Neck Cancer (HNC) Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “PD-1 Resistant Head and Neck Cancer (HNC) – Epidemiology Forecast 2030” drug pipelines have been added to ResearchAndMarkets.com’s offering.

This ‘PD-1 Resistant Head and Neck Cancer – Epidemiology Forecast – 2030’ report deliver an in-depth understanding of and historical and forecasted epidemiology of PD-1 Resistant Head and Neck Cancer in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, South Korea, and Taiwan.

PD-1 Resistant Head and Neck Cancer Epidemiology

The PD-1 Resistant Head and Neck Cancer epidemiology division provide insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.

Key Findings

The total incident cases of PD-1 Resistant Head and Neck Cancer patients are increasing in the studied geography during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted PD-1 Resistant Head and Neck Cancer symptoms epidemiology segmented as the Head and Neck Cancer diagnoses patients, PD-1 treated patients and PD-1 refractory patients. The report includes the prevalent scenario of PD-1 Resistant Head and Neck Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea and Taiwan from 2018 to 2030.

Country-wise PD-1 resistant patients Epidemiology

The epidemiology segment also provides the IO treated patients epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, South Korea and Taiwan.

The total cases of PD-1 resistant patients in the covered geographies were 11,940 in 2020.

  • As per the estimates, the United States has the largest population of PD-1 resistant patients.
  • Among the EU5 countries, France had the highest cases of PD-1 resistant patients. On the other hand, Spain had the lowest cases of PD-1 resistant patients in 2020.

Scope of the Report

  • The PD-1 Resistant Head and Neck Cancer report cover a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The PD-1 Resistant Head and Neck Cancer epidemiology report and model provide an overview of PD-1 Resistant Head and Neck Cancer’s risk factors and global trends in the ten major markets (US, France, Germany, Italy, Spain, UK, Japan, China, South Korea and Taiwan).
  • The report provides insight into PD-1 Resistant Head and Neck Cancer’s historical and forecasted patient pool in ten major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, China, South Korea and Taiwan.
  • The report helps to recognize the growth opportunities in the covered geographies concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of PD-1 Resistant Head and Neck Cancer.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by Head and Neck cancer diagnosed patients in 7MM, China, South Korea and Taiwan.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 treated patients in 7MM, China, South Korea and Taiwan.
  • The report provides the PD-1 Resistant Head and Neck Cancer epidemiology segmentation by PD-1 refractory patients in 7MM, China, South Korea and Taiwan.

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 PD-1 Resistant Head and Neck Cancer Market Overview at a Glance

3.1 Patient Share (%) Distribution of PD-1 Resistant Head and Neck Cancer in 2018

3.2 Market Share (%) Distribution of PD-1 Resistant Head and Neck Cancer in 2030

4 Executive Summary of PD-1 Resistant Head and Neck Cancer

5 Disease Background and Overview

5.1 Pathogenesis

5.2 Molecular Genetics of Head and Neck Cancer

5.3 Types of Head and Neck Cancer

5.4 Symptoms

5.5 Risk factors

5.6 Histopathology

5.7 Diagnosis

5.8 Staging

5.9 NCCN Guidelines

5.10 EHNSe-ESMOe-ESTRO Clinical Practice Guidelines for Squamous cell carcinoma

5.11 ESMO-EURACAN Clinical Practice Guidelines for Nasopharyngeal carcinoma

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 PD-1 refractory patients in 7MM, China, South Korea and Taiwan

6.3 Epidemiology of Checkpoint Inhibitors refractory cancer

6.4 The United States

6.4.1 Head and Neck cancer diagnosed patients in the United States

6.4.2 PD-1 treated patients in the United States

6.4.3 PD-1 refractory patients in the United States

6.5 EU5

6.5.1 Germany

6.5.2 France

6.5.3 Italy

6.5.4 Spain

6.5.5 United Kingdom

6.6 Japan

6.6.1 Head and Neck cancer diagnosed patients in Japan

6.6.2 PD-1 treated patients in Japan

6.6.3 PD-1 refractory patients in Japan

6.7 China

6.8 South Korea

6.9 Taiwan

7 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yquss0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900